Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study.
Maddaloni E, Carlone A, Pitocco D, Leanza G, Suraci C, Altomare M, Cavallo MG, Barchetta I, Morano S, Moretti C, Coraggio L, Visalli N, Tramontana F, Schiaffini R, Crinò A, Buzzetti R, Pozzilli P; IMDIAB study group. Maddaloni E, et al. Among authors: coraggio l. Diabetes Obes Metab. 2023 Nov;25(11):3415-3419. doi: 10.1111/dom.15213. Epub 2023 Jul 14. Diabetes Obes Metab. 2023. PMID: 38014612 No abstract available.
Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a 6 months follow-up study: The CoVaDiab study I.
D'Onofrio L, Fogolari M, Amendolara R, Siena A, De Fata R, Davini F, Coraggio L, Mignogna C, Moretti C, Maddaloni E, Angeletti S, Buzzetti R. D'Onofrio L, et al. Among authors: coraggio l. Diabetes Metab Res Rev. 2023 Mar;39(3):e3601. doi: 10.1002/dmrr.3601. Epub 2022 Dec 27. Diabetes Metab Res Rev. 2023. PMID: 36533777 Free PMC article.
Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Maddaloni E, Coraggio L, Amendolara R, Baroni MG, Cavallo MG, Copetti M, Cossu E, D'Angelo P, D'Onofrio L, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Park K, Holman RR, Trischitta V, Buzzetti R; SUMMER Study in Diabetes Group. Maddaloni E, et al. Among authors: coraggio l. Diabetes Metab Res Rev. 2023 Jul;39(5):e3632. doi: 10.1002/dmrr.3632. Epub 2023 Mar 20. Diabetes Metab Res Rev. 2023. PMID: 36880127
Analysis of prognostic factors in COVID-19 hospitalized patients: an Italian single-center case-control study.
Concistrè A, Petramala L, Pugliano CL, Celi M, Vinci F, Assanto E, Barchetta I, Perrone EP, Rella S, Iannazzo F, Angheloni A, Coraggio L, Di Rienzo F, Maggi D, Circosta F, Galardo G, Muscaritoli M, Letizia C. Concistrè A, et al. Among authors: coraggio l. Eur Rev Med Pharmacol Sci. 2023 Feb;27(3):1207-1221. doi: 10.26355/eurrev_202302_31232. Eur Rev Med Pharmacol Sci. 2023. PMID: 36808370 Free article.
IFN-α neutralizing antibodies distinguish LADA from early-onset type 1 diabetes.
Amendolara R, D'Onofrio L, Sessa RL, Di Giulio S, Mignogna C, Coraggio L, Schirano R, Zampetti S, Malandrucco I, Pozzilli P, Giannini G, Maddaloni E, Buzzetti R. Amendolara R, et al. Among authors: coraggio l. J Clin Endocrinol Metab. 2025 Jan 6:dgaf001. doi: 10.1210/clinem/dgaf001. Online ahead of print. J Clin Endocrinol Metab. 2025. PMID: 39760686
No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study.
Bodini S, Pieralice S, D'Onofrio L, Mignogna C, Coraggio L, Amendolara R, Risi R, Salducci M, Buzzetti R, Maddaloni E. Bodini S, et al. Among authors: coraggio l. Clin Ther. 2024 Nov;46(11):828-834. doi: 10.1016/j.clinthera.2024.04.009. Epub 2024 Jul 4. Clin Ther. 2024. PMID: 38964935 Free article.
Evidence of Partial Seniority Conservation in the πg_{9/2} Shell for the N=50 Isotones.
Pérez-Vidal RM, Gadea A, Domingo-Pardo C, Gargano A, Valiente-Dobón JJ, Clément E, Lemasson A, Coraggio L, Siciliano M, Szilner S, Bast M, Braunroth T, Collado J, Corina A, Dewald A, Doncel M, Dudouet J, de France G, Fransen C, González V, Hüyük T, Jacquot B, John PR, Jungclaus A, Kim YH, Korichi A, Labiche M, Lenzi S, Li H, Ljungvall J, López-Martens A, Mengoni D, Michelagnoli C, Müller-Gatermann C, Napoli DR, Navin A, Quintana B, Ramos D, Rejmund M, Sanchis E, Simpson J, Stezowski O, Wilmsen D, Zielińska M, Boston AJ, Barrientos D, Bednarczyk P, Benzoni G, Birkenbach B, Boston HC, Bracco A, Cederwall B, Cullen DM, Didierjean F, Eberth J, Gottardo A, Goupil J, Harkness-Brennan LJ, Hess H, Judson DS, Kaşkaş A, Korten W, Leoni S, Menegazzo R, Million B, Nyberg J, Podolyak Z, Pullia A, Ralet D, Recchia F, Reiter P, Rezynkina K, Salsac MD, Şenyiğit M, Sohler D, Theisen C, Verney D. Pérez-Vidal RM, et al. Among authors: coraggio l. Phys Rev Lett. 2022 Sep 9;129(11):112501. doi: 10.1103/PhysRevLett.129.112501. Phys Rev Lett. 2022. PMID: 36154392
19 results